n.a. (SNT)

0.12
0.00 (0.00)
AMEX
Prev Close 0.12
Open 0.12
Day Low/High 0.12 / 0.12
52 Wk Low/High 0.11 / 0.32
Exchange AMEX
Div & Yield N.A. (N.A)

Latest News

Senesco Announces Delisting Of Common Stock From NYSE MKT LLC And Pending Transfer To An Over-the-Counter Securities Market

Senesco Announces Delisting Of Common Stock From NYSE MKT LLC And Pending Transfer To An Over-the-Counter Securities Market

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) received verbal notice from NYSE MKT LLC of the exchange’s decision to delist the Company’s common stock from the...

Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results

Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) today reported financial results for the first quarter of fiscal year 2013 which ended on September 30, 2012.

Senesco Announces Expansion Of Phase 1b/2a Study To Include Diffuse Large B-Cell Lymphoma And Mantle Cell Lymphoma

Senesco Announces Expansion Of Phase 1b/2a Study To Include Diffuse Large B-Cell Lymphoma And Mantle Cell Lymphoma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that the clinical trial of SNS01-T has been expanded to include diffuse large B-cell lymphoma (DLBCL) and mantle...

Senesco Technologies Reports Fiscal Year 2012 Financial Results

Senesco Technologies Reports Fiscal Year 2012 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) today announced financial results for the 12 months ended June 30, 2012 (“Fiscal 2012”).

Senesco Announces First Dose Of SNS01-T In Cohort 2 Of Phase 1b/2a Study In Multiple Myeloma Trial

Senesco Announces First Dose Of SNS01-T In Cohort 2 Of Phase 1b/2a Study In Multiple Myeloma Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with...

Combining SNS01-T With Bortezomib Significantly Increases Its Effectiveness In Model Of Multiple Myeloma

Combining SNS01-T With Bortezomib Significantly Increases Its Effectiveness In Model Of Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE ® marketed by Millennium, The Takeda...

Senesco To Present At Rodman & Renshaw Annual Global Investment Conference

Senesco To Present At Rodman & Renshaw Annual Global Investment Conference

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference being held at the...

Senesco Technologies Receives Notice Of Non-Compliance From NYSE MKT

Senesco Technologies Receives Notice Of Non-Compliance From NYSE MKT

On August 22, 2012, Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) received a notice from NYSE Regulation, Inc.

Senesco Announces That SNS01-T Showed Good Tolerability And Stable Disease In Newly Completed First Cohort Of Phase 1b/2a Multiple Myeloma Trial

Senesco Announces That SNS01-T Showed Good Tolerability And Stable Disease In Newly Completed First Cohort Of Phase 1b/2a Multiple Myeloma Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that it has completed the first cohort of patients in its Phase 1b/2a clinical trial for the treatment of multiple...

Senesco Announces Highly Statistically Significant Tumor Growth Inhibition By A Combination Of Lenalidomide And SNS01-T In Cancer Model

Senesco Announces Highly Statistically Significant Tumor Growth Inhibition By A Combination Of Lenalidomide And SNS01-T In Cancer Model

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today the results from the completed non-clinical study of SNS01-T in combination of lenalidomide in a model of...

Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status From FDA For Treatment Of Mantle Cell Lymphoma And Diffuse Large B-Cell Lymphoma

Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status From FDA For Treatment Of Mantle Cell Lymphoma And Diffuse Large B-Cell Lymphoma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that it was informed on July 26 th that the U.

Senesco Provides SNS01-T Update On Phase 1b/2a Multiple Myeloma Trial

Senesco Provides SNS01-T Update On Phase 1b/2a Multiple Myeloma Trial

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster ...

Senesco’s SNS01-T To Be Presented During Poster Session At 2012 Annual Meeting Of The American Society Of Clinical Oncology

Senesco’s SNS01-T To Be Presented During Poster Session At 2012 Annual Meeting Of The American Society Of Clinical Oncology

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT), announced today that a poster describing the ongoing SNS01-T study in multiple myeloma will be presented at the 2012 Annual...

Senesco’s SNS01 Is A Potent Regulator Of Programmed Cell Death And Tumor Growth In Murine Models Of Multiple Myeloma

Senesco’s SNS01 Is A Potent Regulator Of Programmed Cell Death And Tumor Growth In Murine Models Of Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT), announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official...

Senesco Technologies Reports Fiscal 2012 Third Quarter Results

Senesco Technologies Reports Fiscal 2012 Third Quarter Results

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 2012.

Senesco To Present SNS01-T, An EIF5A-based Nanoparticle In A Phase 1b/2a Trial To Treat Multiple Myeloma, Is Effective In Models Of B-Cell Lymphoma

Senesco To Present SNS01-T, An EIF5A-based Nanoparticle In A Phase 1b/2a Trial To Treat Multiple Myeloma, Is Effective In Models Of B-Cell Lymphoma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that an oral presentation will be delivered at the 15 th Annual Meeting of the American Society of Gene &...

Senesco Adds Additional Clinical Site To Evaluate SNS01-T In Multiple Myeloma

Senesco Adds Additional Clinical Site To Evaluate SNS01-T In Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) today announced that it has received Institutional Review Board approval and has finalized a clinical trial research agreement...

Senesco Announces Additional $1.0 Million Equity Financing

Senesco Announces Additional $1.0 Million Equity Financing

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise an additional $1.

Senesco Adds Second Clinical Site To Evaluate SNS01-T In Multiple Myeloma

Senesco Adds Second Clinical Site To Evaluate SNS01-T In Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) today announced that it has received Institutional Review Board approval and has finalized a clinical trial research agreement...

Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results

Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the second quarter of fiscal year 2012 which ended on December 31, 2011.

Senesco Announces $2.0 Million Equity Financing

Senesco Announces $2.0 Million Equity Financing

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise approximately $2.

Senesco And Rahan Meristem (1998) LTD Enter Into New Agreement

Senesco And Rahan Meristem (1998) LTD Enter Into New Agreement

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it has re-structured its research and development agreement with Rahan Meristem (1998) Ltd...

SNS01-T Demonstrates Synergy With Lenalidomide In Cancer Model

SNS01-T Demonstrates Synergy With Lenalidomide In Cancer Model

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that the combination of lenalidomide and SNS01-T, the subject of Senesco’s on-going multiple myeloma...

NYSE Amex Accepts Senesco Technologies’ Plan Of Compliance

Senesco Technologies, Inc. (the “Company” or “Senesco”) (NYSE Amex: SNT) announced today that on December 22, 2011, it received notice from the NYSE Amex LLC (“NYSE”) stating that the...

Senesco To Present At The 53rd Annual Meeting Of The American Society Of Hematology On SNS01-T

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it will deliver a poster presentation at the 53rd Annual Meeting of ASH, the American Society of Hematology.

Senesco Technologies, Inc. Investor Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com

Company invites individual and institutional investors to log-on to view presentation

Senesco Receives Milestone Payment From Bayer CropScience

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that Bayer CropScience has made an undisclosed R&D milestone payment related to Bayer’s use of...

Senesco Technologies, Inc. To Webcast, Live, At RetailInvestorConferences.com On December 1st

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference